Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303

被引：0
|
作者：
Kobayashi, D. [1 ]
Enomoto, A. [2 ]
Mochizuki, Y. [3 ]
Matsui, T. [4 ]
Nakayama, H. [5 ]
Kawase, Y. [6 ]
Ishigure, K. [7 ]
Shikano, T. [8 ]
Torii, K. [9 ]
Kodera, Y. [1 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Gastroenterol Surg, Nagoya, Aichi, Japan
[2] Nagoya Univ, Grad Sch Med, Pathol, Nagoya, Aichi, Japan
[3] Komaki Municipal Hosp, Dept Surg, Komaki, Japan
[4] Aichi Canc Ctr Hosp, Dept Surg, Okazaki, Aichi, Japan
[5] Natl Hosp Org, Dept Surg, Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Tosei Gen Hosp, Dept Surg, Seto, Japan
[7] Konan Kosei Hosp, Dept Surg, Konan, Japan
[8] Yokkaichi Municipal Hosp, Dept Surg, Yokaichi, Japan
[9] Nakatsugawa Municipal Gen Hosp, Dept Surg, Nakatsugawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
696P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Matossian, Margarite
    Saha, Poornima
    Rampurwala, Murtuza
    Kamaraju, Salaija
    Hahn, Olwen
    Howard, Frederick M.
    Fleming, Gini F.
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne
    Nanda, Rita
    Stringer-Reasor, Erica M.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 111 - 119
  • [22] Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC)
    Kolevska, T.
    Ryan, C. J.
    Huey, V.
    Weisberg, L.
    Wang, S.
    Baer, D.
    Ghadialy, A.
    Goldstein, D.
    Fireman, B.
    Fehrenbacher, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302)
    Hirota, Masashi
    Tamura, Shigeyuki
    Taniguchi, Hirokazu
    Takeno, Atsushi
    Imamura, Hiroshi
    Fujita, Junya
    Matsuyama, Jin
    Kimura, Yutaka
    Kawada, Junji
    Hirao, Motohiro
    Nishikawa, Kazuhiro
    Fujitani, Kazumasa
    Kurokawa, Yukinori
    Sakai, Daisuke
    Kawakami, Hisato
    Shimokawa, Toshio
    Satoh, Taroh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [25] Efficacy of nab-paclitaxel vs. Gemcitabine in combination with S-1 for advanced pancreatic cancer: A multicenter phase II randomized trial
    Guo, Xi
    Lou, Wenhui
    Xu, Yaolin
    Zhuang, Rongyuan
    Yao, Lie
    Wu, Junwei
    Fu, Deliang
    Zhang, Jun
    Liu, Jing
    Rong, Yefei
    Jin, Dayong
    Wu, Wenchuan
    Xu, Xuefeng
    Ji, Yuan
    Wu, Lili
    Lv, Minzhi
    Yao, Xiuzhong
    Liu, Xiaowei
    Wang, Dansong
    Kuang, Tiantao
    Liu, Liang
    Wang, Wenquan
    Liu, Tianshu
    Zhou, Yuhong
    ONCOLOGY LETTERS, 2024, 27 (04)
  • [26] Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
    Alberts, David S.
    Blessing, John A.
    Landrum, Lisa M.
    Warshal, David P.
    Martin, Lainie P.
    Rose, Stephen L.
    Bonebrake, Albert J.
    Ramondetta, Lois M.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 451 - 455
  • [27] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [28] Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
    Yannan Zhao
    Fangfang Lv
    She Chen
    Zhonghua Wang
    Jian Zhang
    Sheng Zhang
    Jun Cao
    Leiping Wang
    Enying Cao
    Biyun Wang
    Xichun Hu
    BMC Cancer, 18
  • [29] Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
    Zhao, Yannan
    Lv, Fangfang
    Chen, She
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    Cao, Jun
    Wang, Leiping
    Cao, Enying
    Wang, Biyun
    Hu, Xichun
    BMC CANCER, 2018, 18
  • [30] A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer
    Sato, Sho
    Kunisaki, Chikara
    Tanaka, Yusaku
    Sato, Kei
    Miyamoto, Hiroshi
    Yukawa, Norio
    Fujii, Yoshiro
    Kimura, Jun
    Takagawa, Ryo
    Takahashi, Masazumi
    Kosaka, Takashi
    Akiyama, Hirotoshi
    Saigusa, Yusuke
    Taguri, Masataka
    Yamanaka, Takeharu
    Endo, Itaru
    ANTICANCER RESEARCH, 2018, 38 (12) : 6911 - 6917
12345